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Pentoxifylline inhibits human peritoneal mesothelial cell growth Continuous ambulatory peritoneal dialysis (CAPD)
and collagen synthesis: Effects on TGF-b. has been successfully used as a maintenance regimen of
Background. Prevention or treatment of peritoneal fibros- end-stage renal disease. After long-term treatment withing syndrome has become an important issue in patients on
CAPD, some patients develop membrane failure due tocontinuous ambulatory peritoneal dialysis (CAPD). Recent
evidence has suggested that mesothelial stem cell proliferation repeated peritonitis and unphysiological dialysate solu-
and matrix over-production predispose the development of peri- tion [1]. Studies regarding the pathological changes of
toneal fibrosis. We investigated whether pentoxifylline (PTX) the peritoneum after CAPD have demonstrated the in-affects human peritoneal mesothelial cell (HPMC) growth and
crease of collagen deposition in the submesothelial layercollagen synthesis.
Methods. HPMC was cultured from human omentum by an even in patients without obvious membrane failure [2, 3].
enzymic disaggregation method. Cell proliferation was assayed Therefore, many recent studies have focused on the pre-
using a methyltetrazolium uptake method. Cell cycle analysis vention of peritoneal fibrosis after long-term CAPD [4].was performed by flow cytometry. Collagen synthesis was mea-
Peritoneal mesothelial cells (PMCs) are critical com-sured by 3H-proline incorporation into pepsin-resistant, salt-
ponents of the peritoneal membrane [5]. They partici-precipitated collagen. Prostaglandins and cAMP were deter-
mined by enzyme immunoassay. Northern blot analysis was pate in the inflammatory reactions in the peritoneal cav-
used to determine mRNA expression. ity [6] and are involved in production and remodeling
Results. Our data show that PTX inhibited serum-stimulated
of extracellular matrices (ECM) [5]. During peritonitis,HPMC growth and collagen synthesis in a dose-dependent man-
many cytokines are released from inflammatory cells andner. Cell cycle analysis showed that PTX arrested the HPMCs
in the G1 phase. PTX decreased the procollagen a1 (I) mRNA stimulate the growth and collagen synthesis of peritoneal
expression either stimulated by serum or transforming growth mesothelial cells [7]. Therefore, it is reasonable to specu-
factor-b (TGF-b). PTX did not alter prostaglandins synthesis
late that PMCs play a major role in the pathogenesis ofbut dose-dependently increased intracellular cAMP level. PTX,
peritoneal fibrosis.the same as 3-isobutyl-l-methylxanthine, could potentiate pros-
taglandin E1 (PGE1) increased cAMP levels of HPMC. The Transforming growth factor-b (TGF-b) is an impor-
antimitogenic and antifibrogenic effects of PTX on HPMC tant growth factor involved in ECM modulation and
were reversed by N-[2]-((p-Bromocinnamyl)amino)ethyl]-5-iso-
can increase many ECM proteins synthesis and decreasequinolinesulfonamide (H-89). Therefore, the mechanism of
their degradation [8]. TGF-b is a growth factor vital tothese effects may be due to the phospodiesterase inhibitory
property of PTX. tissue repair, but it may be responsible for tissue fibrosis
Conclusions. These data suggest that PTX may have a role due to excessive action. The role of excessive TGF-b
in treating peritoneal fibrosing syndrome.
activity in disease was first demonstrated in acute mesan-
gial proliferative glomerulonephritis, and has also been
established in other organs, such as the skin, lung, central
nervous system and eye [reviewed in 9]. There is much
evidence to support that TGF-b plays a key role in peri-
toneal healing and adhesiogenesis [10]. Human PMCKey words: cAMP, continuous ambulatory peritoneal dialysis, fibrosis,
mitogenesis, end-stage renal disease, inflammation. have been shown to synthesize TGF-b, and they can
be up-regulated by interleukin (IL)-1b [11]. Frequent
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growth factor involved in peritoneal fibrosis in CAPD sterile phosphate buffered saline (PBS) three times and
then incubated with 15 mL of trypsin-EDTA (0.125%)patients.
Pentoxifylline (PTX) is a xanthine derivative [13] that for 20 minutes in 378C with continuous rotation. After
incubation the omentum and the suspension were centri-is able to inhibit the proliferation and collagen synthesis
of human skin fibroblasts [14] and rat mesangial cells [15]. fuged at 50 3 g for five minutes at 48C. The supernatant
was discarded together with the omentum and the cellBecause human peritoneal mesothelial cells (HPMCs)
have a myofibroblastic nature [16], we hypothesized that pellet was washed once in RPMI-1640 medium con-
taining 20% FCS, penicillin 100 U/mL, streptomycin 100PTX may have similar effects on HPMCs. Therefore,
we investigated whether PTX affected human peritoneal mg/mL, and insulin 30 mg/mL. After another centrifuga-
tion in the same conditions, the cells were resuspendedmesothelial cells growth and collagen synthesis. We also
studied the possible mechanism of its actions and its in the same medium and seeded into a 75 cm2 flask. In
two to four days, the cells became confluent and wereeffect on TGF-b. Our aim was to find an agent to treat
peritoneal fibrosis after long-term CAPD. subcultured with medium containing 10% FCS. The cells
were initially bipolar or multipolar, but become cobble-
stone-like in appearance upon confluence. Mesothelial
METHODS
cells were identified by the presence of vimentin and
Materials cytokeratin and the absence of desmin and factor VIII-
related antigen using the immunofluorescence method.Trypsin-ethylenediaminetetraacetic acid (EDTA),
RPMI-1640 medium, glutamine, and trypan blue were All experiments listed below were performed in passages
1 to 3 cells and were repeated at least three times usingobtained from Gibco (Grand Island, NY, USA). Culture
flasks and plates were purchased from Corning (Corning, cells from different subjects.
NY, USA) and precoated with 1.6 mg/cm2 of Vigtrogen
Cell proliferation assay100t (Celtrix Lab., Palo Alto, CA, USA) before loading
cells. Fetal calf serum (FCS) was obtained from Biochrom A modified MTT assay was used [18]. The MTT uptake
(absorbance at 570 nm) for the HPMC was found toKG (Berlin, Germany). Triton X-100, bovine serum albu-
min, N2,29-O-dibutyryladenosine 39:59-cyclic monophos- vary linearly with cell numbers ranging from 4000 cells/
well to 1.28 3 105 cells/well in 96-well plates, and thephate (DBcAMP), 3-isobutyl-l-methylxanthine (IBMX),
prostaglandin E1 (PGE1), arachidonic acid, indometha- absorbance ranged from 0.08 6 0.01 to 1.14 6 0.09 as
we previously described [19]. Cells growing in the logcin, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide (MTT), PTX, penicillin, streptomycin, insulin, phase were trypsinized and were resuspended in RPMI-
1640 medium containing 10% FCS. We loaded 5000 cell/ascorbic acid, b-aminopropionitrile, and pepsin-contain-
ing acetic acid were purchased from Sigma (St. Louis, well (180 mL of suspension) for proliferation assay in 96-
well plate. Various concentrations of agents were addedMO, USA). N-[2-((p-Bromocinnamyl)amino)ethyl]-5-
isoquinolinesulfonamide (H-89) was brought from Cal- after overnight plating. The medium and drugs were
changed every three days. After an additional incubationbiochem-Novabiochem Corp. (San Diego, CA, USA).
3H-proline was obtained from NEN Dupont (Boston, of 24 to 120 hours, 20 mL MTT solution (5 mg/mL in
PBS) were added to each well of the 96-well plate. AfterMA, USA). The enzyme immunoassay (EIA) kits of cy-
clic adenosine monophosphate (cAMP), 6-keto-prosta- another incubation for four hours at 378C, the medium
was replaced by 100 mL of pure ethanol. Absorbance atglandin F1a (6-keto-PGF1a) and prostaglandin E2 (PGE2)
were purchased from Cayman Chemical Co. (Ann the reference wavelength of 630 nm and test wavelength
of 570 nm were measured by an ELISA reader. AllArbor, MI, USA). Monoclonal antibodies to human des-
min, vimentin, cytokeratin, and factor VIII-related anti- samples were done in pentaplicate. To calculate the per-
centage of inhibition by MTT assay, the following for-gen were from Dako Co. (Kyoto, Japan). Agents used
for Northern blot analysis and RNAse A were from mula was used.
Boehringer Mannheim GmbH (Mannheim, Germany)
% Inhibition 5
unless otherwise specified. Propidium iodide was pur-
chased from ICN Biomedicals Inc. (Aurora, OH, USA).
51 2
Absorbance of
(Test dose 2 initial plating)
Absorbance of
(Control 2 initial plating)
6 3 100%Human peritoneal mesothelial cell cultureSpecimens of human omentum were obtained from
abdominal surgical procedures with informed consent.
For cell counting, freshly trypsinized HPMCs (2.5 3These patients underwent elective abdominal surgery
104 cells/well) were loaded in 24-well plates. After over-and the omentum was normal. The method of enzymatic
night plating, various concentrations of PTX were added.disaggregation of omentum were used as previously de-
scribed [17]. Briefly, a piece of omentum was washed in The medium and PTX were changed every three days.
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After an additional incubation of 24 to 120 hours, cell hours, cultures were labeled with 0.5 mCi of 3H-proline
(100 Ci/mmole; ICN) and 50 mg/mL b-aminopropio-counting was performed by a Coulter counter. All experi-
ments were done in triplicate. nitrile for the final 24 hours of incubation [14]. The
3H-proline incorporation into pepsin-resistant, salt-pre-
Cell viability test cipitated collagen was determined as previously de-
scribed [22]. After termination of incubation, 3H-prolineTo exclude the toxic effect of PTX on HPMC, after
incubating with various doses of PTX for various periods labeled collagen was extracted from each well by the
addition of pepsin-containing acetic acid (final concen-of time in 24-well plates, cell viability was assessed by
the trypan blue exclusion method [20]. The number of tration of 1 mg/mL in 1 mol/L acetic acid) and purified
by successive salt precipitation at acid and neutral pHdead cells from the supernatant of each well was counted
and the proportion of dead cells from the cells adhering in the presence of carrier collagen. The final precipitates
were dissolved in 0.5 mol/L acetic acid, incorporated intoto the plates were also counted in separate wells by
applying trypan blue directly on the cells. All samples a scintillation cocktail and counted by a liquid scintilla-
tion counter. Cell numbers were simultaneously countedwere tested in triplicate.
by MTT assay in identically treated microplates and the
Test of injury to HPMC plasmalemma collagen synthetic amount was factored by the same
treated MTT. All experiments were done in triplicate.To exclude the toxicity of PTX to the integrity of
HPMC plasmalemma, the leakage of lactate dehydroge-
Northern blot analysisnase (LDH) from the cytosol of HPMC was measured.
HPMCs were plated at a density of 5 3 104 cells/well in Human PMCs were cultured in a 50 cm2 dish with
10% FCS-containing RPMI to a confluent monolayer.a 24-well plate and grown to a confluent monolayer.
Then the medium was replaced by 0.5 mL RPMI-1640 After growth arrest for two days with 0.5% FCS-con-
taining RPMI, the supernatants were then replaced withmedium with 0.5% FCS after being washed twice with
warm PBS. Various concentrations of PTX were added, 10% FCS-containing RPMI with various concentrations
of PTX. For the experiments involving TGF-b, 0.5%and 0.015% Triton X-100 was added as a positive control.
The plates were incubated for one, three and five days, FCS-containing RPMI with various concentrations of
agents were added. At various time intervals, the totalrespectively, and then the medium was removed and the
LDH activity was measured by an enzymatic method RNA was isolated using the acid guanidinium thiocya-
natephenol-chloroform method, as previously described[21]. All experiments were done in quadruplicate.
[23]. The amount of RNA was quantified using spectro-
Cell cycle distribution photometry with absorbance at 260 nm. Ten micrograms
of RNA were then electrophoresed on a 1% agarose gelHuman PMCs were cultured in a 50 cm2 dish with 10%
FCS-containing RPMI until they became subconfluent. containing 1.0 mol/L formaldehyde in MOPS buffer (0.2
mol/L morpholinopropanesulfonic acid, 0.05 mol/L ace-After growth arrest for two days with 0.5% FCS-con-
taining RPMI, cells were treated with 10% FCS-con- tate, 0.01 mol/L EDTA). Equivalency of sample loading
and lack of degradation were verified by ethidium bro-taining RPMI with or without PTX. Cells were trypsin-
ized and resuspended in PBS at a concentration of 2 3 mide staining of 28 S and 18 S rRNA bands. The RNA
was transferred to nylon membranes by overnight capil-106/mL after incubating for 24 hours. One milliliter of
the suspension was fixed in 2 mL methanol for 30 minutes lary action and followed by fixation in an UV cross-
linker.at 48C, and the mixture was incubated in 0.5 mL of
propidium iodide solution (0.05 mg/mL in 3.8 mol/L Na Because HPMCs mainly express type I and type III
collagens [24], hybridization of the Northern blots wascitrate) and 0.5 mL of RNAse A (0.5 mg/mL) at room
temperature for 30 minutes. Cells were finally resus- performed with a cRNA probe for 1.5-kb human type I
collagen [procollagen a1 (I)]. The cRNA probes werepended in 1 mL PBS and analyzed by flow cytometry
(FACScan; Coulter) according to the manufacturer’s in- transcribed using phage T3 and T7 DNA-dependent
RNA polymerase in the presence of digoxigenin-UTPstructions. All experiments were done in triplicate.
as described by the supplier, from subcloned templates
Collagen synthesis corresponding to a 1.5-kb EcoR1 fragment from human
procollagen a 1 (I) cDNA (HF677; ATCC, Rockville,Human PMCs were plated at a density of 2.5 3 104
cells/well in a 96-well plate in 200 mL medium supple- MD, USA). The RNA blots were prehybridized for three
hours at 658C in a hybridization solution composed ofmented with 10% FCS. After incubation for 48 hours,
the cells became confluent. Then the medium was re- 50% formamide, 5 3 SSC (1 3 5 120 mmol/L NaCl, 15
mmol/L Na citrate, 13 mmol/L KH2PO4 and 1 mmol/Lplaced by 10% FCS-supplemented medium containing
50 mg/mL of ascorbic acid with or without different con- EDTA, pH 7.2), 0.1% Na lauryl sarcosine, 2% Na dode-
cyl sulfate (SDS) and 5% blocking reagent, then hybrid-centrations of PTX. After additional incubation of 48
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Fig. 2. Collagen synthesis of HPMCs in the presence of various concen-
trations of PTX. The result is expressed as the percentage of the control.
All data are expressed as the means with SD of 3 experiments conducted
in triplicate. Details of the method are in the text. *P , 0.05 vs. control.
10% FCS. The plating efficiency was about 90%. After
three to five days, the cells became confluent, they were
washed twice with warm RPMI-1640 medium and then
various concentrations of agents were added. After five
minutes incubation, the supernatants were discarded and
ice-cold 95% methanol/5% formic acid solution added
to each well. After 30 minutes incubation at 48C, the
supernatants were evaporated and cAMP were mea-
sured by EIA. The cells of each well were lysed with 0.1
N NaOH and the protein contents were measured by
bicinchoninic acid assay, with bovine serum albumin as
Fig. 1. Pentoxifylline (PTX) inhibits human peritoneal mesothelial cell the standard [25]. All experiments were done in quadru-
(HPMC) growth. (A) Time response curve. Various concentrations of plicate.
PTX [0 (j), 0.01 (d), 0.03 (r), 0.1 (.), and 0.3 (m) mg/mL] were
added after overnight plating of HPMCs and the cells were further PGE2 and 6-keto-PGF1a assayincubated for 1 to 5 days, and then an MTT assay was performed. Data
represent one of the 3 experiments. (B) Dose response curve. Cells Seventy thousand HPMCs per well were loaded into
were incubated for 5 days after addition of various concentrations of 24-well plates and cultured in medium supplementedPTX, and then an MTT assay was performed. All data are expressed
with 10% FCS. After the cells became confluent, theyas the means with SD of 3 experiments conducted in pentaplicate. *P ,
0.05 vs. control. were washed twice with warm RPMI-1640 medium, and
then various concentrations of agents were added and
incubated for one hour. The supernatants were collected
and PGE2 and 6-keto-PGF1a [the stable metabolite of
ized overnight at 658C with 20 ng/mL probe in the same prostacyclin (PGI2)] levels were assayed by EIA. The
solution, followed by washing in 2 3 SCC/0.1% SDS protein content of each well was determined by bicin-
and 0.1 3 SSC/0.1% SDS at 658C. The blots were devel- choninic acid assay. All experiments were done in qua-
oped using alkaline phosphatase conjugated antidigoxi- druplicate.
genin antibody at Lumi-phos 530 according to the manu-
Statistical analysisfacturer’s directions. The signal intensity recorded on x-ray
All data are expressed by mean 6 SD. The comparisonfilm was quantified by computerized densitometry. The
of dose effect was done by a one-way ANOVA followedblots were also probed with cRNA for glyceraldehyde-
by Student’s t-test. A P value less than 0.05 was consid-3-phosphate dehydrogenase (GAPDH) to control for
ered significant.variations in RNA loading and transfer.
Intracellular cAMP measurements RESULTS
Fifty thousand HPMCs per well were loaded into a At the concentrations below 0.3 mg/mL (1.08 mmol/L),
PTX caused a dose-dependent inhibition of serum-stimu-24-well plate and cultured in medium supplemented with
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Fig. 3. Northern blot analysis of mRNA iso-
lated from HPMC incubated with or without
PTX. The RNA blots were hybridized with
procollagen a1 (I) and GAPDH cRNA probes.
Cells were treated with PTX 0.3 mg/mL for 4
hours (1), 0.3 mg/mL for 8 hours (2), 0.3
mg/mL for 16 hours (3), 0.1 mg/mL for 16
hours (4), 0.03 mg/mL for 16 hours (5), and
0.3 mg/mL for 24 hours (6). C is control.
Fig. 4. Northern blot analysis of mRNA iso-
lated from HPMC. The RNA blots were hy-
bridized with procollagen a1 (I) and GAPDH
cRNA probes (A), or procollagen a1 (III) and
GAPDH cRNA probes (B). Cells were treated
with agents for 16 hours. Control (1), 1 ng/mL
of TGF-b (2), 1 ng/mL of TGF-b and 0.3
mg/mL of PTX (3).
lated HPMC growth (Fig. 1). The percentage of inhibi- that PTX decreased serum-stimulated procollagen a1
(I) mRNA expression while GAPDH mRNA was nottion for concentration at 0.3 mg/mL was 77%. This anti-
mitogenic effect was confirmed by cell counting five days affected. The time course and dose response effect of
PTX on procollagen a1 (I) mRNA are shown in Figureafter added various concentrations of PTX (control,
8.35 6 0.61 3 104/well; PTX 0.03 mg/mL, 6.13 6 0.58 3 3. Maximal decrease of procollagen a1 (I) mRNA levels
was observed at 16 hours after the addition of 0.3 mg/mL104/well, PTX 0.1 mg/mL, 5.44 6 0.52 3 104/well; PTX
0.3 mg/mL, 3.32 6 0.46 3 104/well; N 5 3, P , 0.05 PTX (.50% decrease). After 16 hours of incubation,
1 ng/mL of TGF-b increased collagen gene transcriptionamong control and each dose of PTX). The cell viability
was confirmed by the trypan blue test, which showed by 100% and PTX inhibited the effect of TGF-b on
collagen I and III gene expression. At the concentrationthat there were no differences in both supernatant and
adherent cells fraction between control and PTX-treated of 0.3 mg/mL, PTX decreased 20% procollagen a1 (I)
mRNA expression compared with that treated withwells. The dead cells of each well were less than 1% of
the total cells. The levels of LDH did not elevate after TGF-b alone (Fig. 4).
The results in intracellular cAMP levels are shown inone-, three-, and five-day incubation periods in PTX-
treated wells, which excluded the cell membrane damage Table 1. The cAMP levels were elevated by PTX in a
dose dependent manner. The PGE1 increased cAMPby PTX on the HPMC (data not shown). Cell cycle analy-
sis showed that PTX arrests the HPMCs in the G1 phase. levels at 10 mmol/L, which was potentiated by the pres-
ence of 0.3 mg/mL PTX or 0.5 mmol/L IBMX. WhileAfter PTX treatment for 24 hours, more cells were in G1
phase than control (control, 42.1 6 3.5%; PTX 0.1 mg/mL, combining various concentrations of PTX and 0.5 mmol/L
IBMX, there was no significant elevation of cAMP when51.3 6 0.8%; PTX 0.3 mg/mL, 62.2 6 2.4%; N 5 3, P ,
0.05 among control and each dose of PTX). compared with IBMX alone. To further clarify that the
effects of PTX on HPMC are through the cAMP path-The collagen synthesis of confluent HPMCs was sup-
pressed by PTX in a dose dependent manner (Fig. 2). way, H-89, a selective PKA inhibitor [26, 27], was added
with and without PTX. When HPMCs were pretreatedThe mRNA expression of type I collagen was measured
after adding PTX. The results of densitometry showed with 10 mmol/L of H-89 for 30 minutes, the antimitogenic
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Table 1. Changes of intracellular cAMP (pmol/mg protein) in




PTX 0.03 mg/mL 86.7635.7a 2946226
PTX 0.3 mg/mL 105641a 3086236
PTX 0.3 mg/mL 193693a 3746316
PGE1 10 lmol/L 484644a 11436379ab
PTX 0.3 mg/mL 1 PGE1 10 lmol/L 9176260ab —
Data are expressed as mean 6 SD of 3 experiments conducted in quadrupli-
cate. Abbreviations are: IBMX, 3-isobutyl-l-methylxanthine; PTX, pentoxifyl-
line; PGE1, prostaglandin E1.
aP , 0.05 vs. control
bP , 0.05 vs. PGE1 10 mmol/L alone Fig. 6. Northern blot analysis of mRNA isolated from HPMC. The
RNA blots were hybridized with procollagen a1 (I) and GAPDH cRNA
probes and GAPDH cRNA probes. Cells were pretreated with 10
mmol/L of H-89 and then with/without 0.1 mg/mL of PTX for 16 hours.
Control (C), 0.1 mg/mL of PTX (1), 10 mmol/L of H-89 (2), and 10
mmol/L of H-89 with 0.1 mg/mL of PTX (3).
Fig. 5. MTT assay on the fifth day after adding 10 mmol/L of H-89
(pretreated for 30 min) with and without 0.1 mg/mL of PTX. All data
are expressed as the means with SD of 3 experiments conducted in
pentaplicate. Abbreviations are: I, initial plating at day 0; C, control;
Fig. 7. MTT assay on the fifth day after adding 10 mmol/L of indometh-PTX, 0.1 mg/mL of PTX; H, 10 mmol/L of H-89. *P , 0.05 vs. control.
acin with and without 0.1 mg/mL of PTX. All data are expressed as
the means with SD of 3 experiments conducted in pentaplicate. Abbrevi-
ations are: I, initial plating at day 0; C, control; PTX, 0.1 mg/mL of
PTX; Id, 10 mmol/L of indomethacin. *P , 0.05 vs. control.
effect of PTX was reversed (Fig. 5). Northern blotting
showed that the effect of PTX on procollagen a1 (I)
mRNA expression was also reversed by H-89 (Fig. 6).
the most possible pathophysiologic process of peritonealTo test whether PTX inhibits HPMC growth through
fibrosis [4, 28, 29]. Studies of the composition of perito-arachidonic acid metabolites, 10 mmol/L of indomethacin
neal fibrotic lesions suggest that these lesions representwas added with and without 0.1 mg/mL of PTX. The
an accumulation of type I and type III collagen as wellantimitogenic effect of PTX (0.1 mg/mL) was not altered
as other matrix proteins such as fibronectin [24]. Agentsby indomethacin (Fig. 7). The PTX also did not stimulate
which can inhibit peritoneal mesothelial stem cell prolif-the 6-keto-PGF1a or PGE2 synthesis of HPMCs in the
eration and/or collagen synthesis may be beneficial in thedose range of antimitogenesis (Table 2).
prevention or retardation of the progress of peritoneal
fibrosis. Because HPMCs in culture have been shown
DISCUSSION to possess the same immunocytochemical markers as
peritoneal mesothelial stem cells (co-expression of cy-One of the most serious complications after long-term
CAPD is peritoneal fibrosis, which causes the perito- tokeratins and vimentin) [16, 30], this culture system can
be used as a tool to study the behaviour of peritonealneum to lose its function and forces the patients to dis-
continue from CAPD due to membrane failure or even stem cells. In this study, we showed that PTX inhibited
HPMC growth and collagen synthesis in vitro. Therefore,suffer from intestinal obstruction [4]. Proliferation of
peritoneal mesothelial stem cells accompanied by over- PTX may be useful in those conditions associated with
mesothelial stem cell overgrowth and/or matrix expan-production of fibrous tissue is currently thought to be
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Table 2. Changes of PGE2 and 6-keto-PGF1a in HPMCs might not reflect the tissue levels, and a higher concen-
tration may be achieved in the peritoneal cavity throughPGE2 6-keto-PGF1a
(pg/ng protein) (pg/ng protein) the intraperitoneal route in patients during CAPD. There-
Control 1.060.3 6.462.3 fore, PTX may be a candidate for clinical use in prevent-
PTX 0.03 mg/mL 0.860.2 5.863.5 ing or treating peritoneal fibrosis, especially when pro-
PTX 0.1 mg/mL 0.760.3 8.365.9
tracted peritonitis results in cytokines/growth factorsPTX 0.3 mg/mL 0.860.1 7.463.5
Arachidonic acid 10 lg/mL 48.5614.7a 63.6618.9a release and extracellular matrix accumulations. Previous
Arachidonic acid 10 lg/mL 1 reports have demonstrated the prevention of liver fibro-
indomethacin 10 lmol/L 9.862.8ab 23.567.2ab
sis in a pig model [34], and the reduction of intraperito-
Data are expressed as mean 6 SD of 3 experiments conducted in quadruplicate. neal adhesions after intestinal resection in a rat modelaP , 0.05 vs. control
bP , 0.05 vs. arachidonic acid alone [35]. Our data give a good explanation of the effect of
PTX on peritoneal fibrosis. Because PTX is a safe and
clinically used drug, it warrants a further in vivo study
to determine its effects on peritoneal fibrosis due to
sion. These include peritoneal fibrosing syndrome rang- CAPD therapy.
ing from mild peritoneal opacification to severe scleros- In conclusion, PTX inhibits HPMC growth and colla-
ing peritonitis. gen synthesis in vitro through the cAMP pathway. Our
Transforming growth factor-b is an important factor data show a potential role of PTX in preventing or treat-
involved in peritoneal fibrosis in patients with CAPD. ing peritoneal fibrosis in CAPD therapy. However, these
TGF-b has been shown to be present in CAPD effluent are only in vitro observations, and further in vivo study
[31] and the amount may predict the presence of perito- is needed to clarify the effects of PTX on peritoneal
neal fibrosis [12]. Since high levels of glucose induce fibrosis due to CAPD therapy.
TGF-b mRNA expression in HPMC [32], glucose-con-
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